Stefanie Hahner

List of Publications by Year
in descending order

Version: 2024-02-01

146 papers	11,783 citations	32410 55 h-index	32181 105 g-index
160 all docs	160 docs citations	160 times ranked	7745 citing authors

#	Article	IF	Citations
1	Reassessment of Postural Stimulation Testing as a Simple Tool to Identify a Subgroup of Patients With Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e865-e873.	1.8	7
2	Adrenal functional imaging. Presse Medicale, 2022, 51, 104114.	0.8	3
3	Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using ⁶⁸Ga-PentixaFor PET. Journal of Nuclear Medicine, 2022, , jnumed.121.263693.	2.8	27
4	Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET/CT. Molecular Imaging and Biology, 2022, 24, 659-665.	1.3	17
5	Primary hyperaldosteronism induces congruent alterations of sodium homeostasis in different skeletal muscles: a 23Na-MRI study. European Journal of Endocrinology, 2022, 186, K33-K38.	1.9	8
6	Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1348-e1355.	1.8	5
7	CXCR4-targeted theranostics in oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4133-4144.	3.3	48
8	Non-invasive assessment of tissue sodium content in patients with primary adrenal insufficiency. European Journal of Endocrinology, 2022, 187, 383-390.	1.9	5
9	Predicitve Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer. Hormone and Metabolic Research, 2021, 53, 24-31.	0.7	1
10	Therapeutic Patient Education for Adrenal Insufficiency under COVID-19 Pandemic Conditions. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 241-249.	0.6	9
11	Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis. Endocrine, 2021, 71, 586-594.	1.1	31
12	Adrenal insufficiency. Nature Reviews Disease Primers, 2021, 7, 19.	18.1	64
13	Novel CYP11B-ligand [123/131I]IMAZA as promising theranostic tool for adrenocortical tumors: comprehensive preclinical characterization and first clinical experience. European Journal of Nuclear Medicine and Molecular Imaging, 2021, , 1.	3.3	7
14	Management of Patients With Glucocorticoid-Related Diseases and COVID-19. Frontiers in Endocrinology, 2021, 12, 705214.	1.5	15
15	Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS. European Journal of Endocrinology, 2021, 184, 167-178.	1.9	11
16	Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): a prospective non-interventional follow-up study. BMC Endocrine Disorders, 2021, 21, 11.	0.9	2
17	Expression of the Chemokine Receptor CCR7 in the Normal Adrenal Gland and Adrenal Tumors and Its Correlation with Clinical Outcome in Adrenocortical Carcinoma. Cancers, 2021, 13, 5693.	1.7	1
18	Glucocorticoid Receptor Polymorphisms Influence Muscle Strength in Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 305-313.	1.8	14

#	Article	IF	Citations
19	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	5.5	129
20	Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma. Frontiers in Endocrinology, 2020, 11, 597878.	1.5	18
21	Current Management and Outcome of Pregnancies in Women With Adrenal Insufficiency: Experience from a Multicenter Survey. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2853-e2863.	1.8	30
22	Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism. Endocrine, 2020, 69, 625-633.	1.1	10
23	Standardised patient education in adrenal insufficiency: a prospective multi-centre evaluation. European Journal of Endocrinology, 2020, 183, 119-127.	1.9	18
24	A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 2019, 188, 38-47.	1.2	4
25	An Update on Addisonâ€™s Disease. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 165-175.	0.6	57
26	Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. Annals of Surgical Oncology, 2019, 26, 531-538.	0.7	22
27	Advanced Adrenocortical Carcinoma â€“ What to do when First-Line Therapy Fails?. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 109-116.	0.6	43
28	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 578-584.	0.6	15
29	Increased myocardial sodium signal intensity in Connâ€™s syndrome detected by 23Na magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2019, 20, 263-270.	0.5	32
30	Emergency treatment of adrenal crisis with prednisone suppositories: a bioequivalence study in female patients with Addisonâ€™s disease. Endocrine Connections, 2019, 8, 425-434.	0.8	5
31	Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. European Journal of Endocrinology, 2019, 180, 117-125.	1.9	59
32	MON-525 Cardiovascular Status in Chronic Hypoparathyroidism: A Prospective Single-Center Analysis in 143 Patients. Journal of the Endocrine Society, 2019, 3, .	0.1	0
33	Management of adrenal emergencies in educated patients with adrenal insufficiencyâ€”A prospective study. Clinical Endocrinology, 2018, 89, 22-29.	1.2	31
34	Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1686-1695.	1.8	105
35	Primary aldosteronism: key characteristics at diagnosis: a trend toward milder forms. European Journal of Endocrinology, 2018, 178, 605-611.	1.9	26
36	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension, 2018, 71, 317-325.	1.3	77

#	Article	IF	Citations
37	Acute adrenal crisis and mortality in adrenal insufficiency: Still a concern in 2018!. Annales D'Endocrinologie, 2018, 79, 164-166.	0.6	25
38	The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53^{wild type} Neuroendocrine Tumor Cell Line GOT1. Neuroendocrinology, 2018, 106, 1-19.	1.2	25
39	Understanding adrenal crisis. Intensive Care Medicine, 2018, 44, 652-655.	3.9	12
40	Magnetic resonance cold pressor test to investigate potential endothelial dysfunction in patients suffering from type 1 diabetes. Journal of Magnetic Resonance Imaging, 2018, 48, 1595-1601.	1.9	3
41	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 650-657.	1.3	51
42	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649.	1.3	94
43	Surviving ectopic Cushingâ€™s syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushingâ€™s disease during long-term follow-up. European Journal of Endocrinology, 2018, 179, 109-116.	1.9	24
44	Management of adrenal emergencies in educated patients with adrenal insufficiencyâ€”A prospective study. , 2018, 89, 22.		1
45	Immediate versus modified release hydrocortisone in mitotaneâ€treated patients with adrenocortical cancer. Clinical Endocrinology, 2017, 86, 499-505.	1.2	5
46	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	7.7	532
47	Changes in Body Mass Index in Pheochromocytoma Patients Following Adrenalectomy. Hormone and Metabolic Research, 2017, 49, 208-213.	0.7	11
48	Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1358-1365.	1.8	108
49	Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. Clinical Nuclear Medicine, 2017, 42, e29-e34.	0.7	60
50	Persistence of myopathy in Cushingâ€™s syndrome: evaluation of the German Cushingâ€™s Registry. European Journal of Endocrinology, 2017, 176, 737-746.	1.9	57
51	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight, 2017, 2, .	2.3	187
52	Prevalence of Malignancies in Patients With Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1656-1663.	1.8	8
53	Worsening of lipid metabolism after successful treatment of primary aldosteronism. Endocrine, 2016, 54, 198-205.	1.1	22
54	Quality of Life and Life Expectancy in Patients with Adrenal Insufficiency: What Is True and What Is Urban Myth. Frontiers of Hormone Research, 2016, 46, 171-183.	1.0	9

#	Article	IF	Citations
55	Assessment of tumor heterogeneity in treatment-naÃ¯ve adrenocortical cancer patients using 18F-FDG positron emission tomography. Endocrine, 2016, 53, 791-800.	1.1	8
56	5th International ACC Symposium: Imaging for Diagnosis and Surveillance of Adrenal Tumorsâ€"New Advances and Reviews of Old Concepts. Hormones and Cancer, 2016, 7, 40-43.	4.9	6
57	Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. Hormones and Cancer, 2016, 7, 211-218.	4.9	16
58	Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4604-4611.	1.8	19
59	Is DHEA replacement beneficial in chronic adrenal failure?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 25-32.	2.2	12
60	High Incidence of Adrenal Crisis in Educated Patients With Chronic Adrenal Insufficiency: A Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 407-416.	1.8	308
61	Eya4 Induces Hypertrophy via Regulation of p27 ^{kip1}. Circulation: Cardiovascular Genetics, 2015, 8, 752-764.	5.1	11
62	Prognostic factors in stage IIIâ€"IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of Oncology, 2015, 26, 2119-2125.	0.6	196
63	Timelines in the management of adrenal crisis â€" targets, limits and reality. Clinical Endocrinology, 2015, 82, 497-502.	1.2	48
64	Diagnosis and management of adrenal insufficiency. Lancet Diabetes and Endocrinology,the, 2015, 3, 216-226.	5.5	297
65	Timelines in the management of adrenal crisis â€" targets, limits and reality. , 2015, 82, 497.		1
66	Outcome of Adrenal Vein Sampling Performed During Concurrent Mineralocorticoid Receptor Antagonist Therapy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4397-4402.	1.8	58
67	Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma. European Journal of Endocrinology, 2014, 170, 707-717.	1.9	8
68	Saving lives of patients with adrenal insufficiency: a panâ€<scp>E</scp>uropean initiative?. Clinical Endocrinology, 2014, 80, 319-321.	1.2	21
69	Suspected metastatic adrenocortical carcinoma revealing as pulmonary Kaposi sarcoma in adrenal Cushingâ€™s syndrome. BMC Endocrine Disorders, 2014, 14, 63.	0.9	3
70	Saving lives of patients with adrenal insufficiency: a pan-European initiative?. , 2014, 80, 319.		1
71	Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5Î±-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 161-171.	1.8	131
72	Genotype-Phenotype Correlation in 153 Adult Patients With Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency: Analysis of the United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE) Cohort. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E346-E354.	1.8	90

#	Article	IF	Citations
73	Functional Characterization of Adrenal Lesions Using [123I]IMTO-SPECT/CT. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1508-1518.	1.8	47
74	[123I]Iodometomidate Imaging in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2755-2764.	1.8	45
75	[³H]Metyrapol and 4-[¹³¹I]Iodometomidate Label Overlapping, but Not Identical, Binding Sites on Rat Adrenal Membranes. Molecular Pharmaceutics, 2013, 10, 1119-1130.	2.3	9
76	The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 181-191.	1.8	132
77	Assay Characteristics Influence the Aldosterone to Renin Ratio as a Screening Tool for Primary Aldosteronism: Results of the German Conn's Registry. Hormone and Metabolic Research, 2013, 45, 526-531.	0.7	22
78	Quality of life in adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE). European Journal of Endocrinology, 2013, 168, 887-893.	1.9	67
79	Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. European Journal of Endocrinology, 2013, 169, 147-154.	1.9	70
80	Tumor Localization in Ectopic Cushing Syndrome Using Combined PET/CT Imaging. Clinical Nuclear Medicine, 2013, 38, 749-751.	0.7	7
81	Adrenal Cortical Insufficiency. Deutsches Ärzteblatt International, 2013, 110, 882-8.	0.6	47
82	Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. European Journal of Endocrinology, 2012, 167, 35-42.	1.9	111
83	[131I]Iodometomidate for Targeted Radionuclide Therapy of Advanced Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 914-922.	1.8	70
84	Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3495-3503.	1.8	146
85	TP53Germline Mutations in Adult Patients with Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E476-E485.	1.8	89
86	Observational Study Mortality in Treated Primary Aldosteronism. Hypertension, 2012, 60, 618-624.	1.3	235
87	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine, 2012, 366, 2189-2197.	13.9	692
88	Dehydroepiandrosterone and androstenedione. , 2012, , 437-458.		3
89	Prevalence, Clinical, and Molecular Correlates of KCNJ5 Mutations in Primary Aldosteronism. Hypertension, 2012, 59, 592-598.	1.3	246
90	What is the best longâ€term management strategy for patients with primary adrenal insufficiency?. Clinical Endocrinology, 2012, 76, 21-25.	1.2	41

#	Article	IF	Citations
91	What is the best long-term management strategy for patients with primary adrenal insufficiency?. , 2012, 76, 21.		1
92	Quality of life is less impaired in adults with congenital adrenal hyperplasia because of 21-hydroxylase deficiency than in patients with primary adrenal insufficiency. Clinical Endocrinology, 2011, 74, 166-173.	1.2	61
93	Metomidate-Based Imaging of Adrenal Masses. Hormones and Cancer, 2011, 2, 348-353.	4.9	35
94	Addisonian crisis in a young man with atypical anorexia nervosa. Nature Reviews Endocrinology, 2011, 7, 115-121.	4.3	12
95	Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3775-3784.	1.8	369
96	Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. European Heart Journal, 2011, 32, 1275-1286.	1.0	51
97	Delayed Diagnosis of Adrenal Insufficiency Is Common: A Cross-Sectional Study in 216 Patients. American Journal of the Medical Sciences, 2010, 339, 525-531.	0.4	165
98	Laparoscopic Versus Open Adrenalectomy for Adrenocortical Carcinoma: Surgical and Oncologic Outcome in 152 Patients. European Urology, 2010, 58, 609-615.	0.9	246
99	Influence of hydrocortisone dosage scheme on healthâ€related quality of life in patients with adrenal insufficiency. Clinical Endocrinology, 2010, 72, 297-304.	1.2	124
100	Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. European Journal of Endocrinology, 2010, 162, 349-356.	1.9	119
101	Health Status of Adults with Congenital Adrenal Hyperplasia: A Cohort Study of 203 Patients. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5110-5121.	1.8	408
102	Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. European Journal of Endocrinology, 2010, 162, 597-602.	1.9	274
103	Evaluation of a Standardized Protocol for Processing Adrenal Tumor Samples: Preparation for a European Adrenal Tumor Bank. Hormone and Metabolic Research, 2010, 42, 93-101.	0.7	20
104	Is Primary Aldosteronism Associated with Diabetes Mellitus? Results of the German Conn's Registry. Hormone and Metabolic Research, 2010, 42, 435-439.	0.7	91
105	Improved Survival in Patients with Stage II Adrenocortical Carcinoma Followed Up Prospectively by Specialized Centers. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4925-4932.	1.8	150
106	Etomidate Unmasks Intraadrenal Regulation of Steroidogenesis and Proliferation in Adrenal Cortical Cell Lines. Hormone and Metabolic Research, 2010, 42, 528-534.	0.7	14
107	Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Modern Pathology, 2010, 23, 1596-1604.	2.9	46
108	High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E161-E171.	1.8	196

#	Article	IF	Citations
109	Dehydroepiandrosterone to Enhance Physical Performance: Myth and Reality. Endocrinology and Metabolism Clinics of North America, 2010, 39, 127-139.	1.2	13
110	Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany. Deutsches Ärzteblatt International, 2010, 107, 885-91.	0.6	44
111	Altered insulin requirement in patients with type 1 diabetes and primary adrenal insufficiency receiving standard glucocorticoid replacement therapy. European Journal of Endocrinology, 2009, 160, 919-924.	1.9	31
112	Cardiovascular and Cerebrovascular Comorbidities of Hypokalemic and Normokalemic Primary Aldosteronism: Results of the German Connâ€™s Registry. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1125-1130.	1.8	237
113	Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocrine-Related Cancer, 2009, 16, 919-928.	1.6	71
114	Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocrine-Related Cancer, 2009, 16, 907-918.	1.6	63
115	Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. Cancer, 2009, 115, 243-250.	2.0	597
116	Radiotherapy in adrenocortical carcinoma. Cancer, 2009, 115, 2816-2823.	2.0	165
117	Osteopontin stimulates invasion of NCIâ€h295 cells but is not associated with survival in adrenocortical carcinoma. Journal of Pathology, 2009, 218, 232-240.	2.1	13
118	The rs1990760 polymorphism within the IFIH1 locus is not associated with Graves' disease, Hashimoto's thyroiditis and Addison's disease. BMC Medical Genetics, 2009, 10, 126.	2.1	16
119	Therapeutic management of adrenal insufficiency. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 167-179.	2.2	49
120	The Diagnosis and Treatment of Primary Hyperaldosteronism in Germany. Deutsches Ärzteblatt International, 2009, 106, 305-11.	0.6	47
121	Insulin gene polymorphisms in type 1 diabetes, Addison's disease and the polyglandular autoimmune syndrome type II. BMC Medical Genetics, 2008, 9, 65.	2.1	10
122	New Selective Inhibitors of Steroid 11Î²-Hydroxylation in the Adrenal Cortex. Synthesis and Structureâ"Activity Relationship of Potent Etomidate Analogues. Journal of Medicinal Chemistry, 2008, 51, 7652-7652.	2.9	1
123	Treatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2057-2062.	1.8	141
124	New Selective Inhibitors of Steroid 11Î²-Hydroxylation in the Adrenal Cortex. Synthesis and Structureâ€"Activity Relationship of Potent Etomidate Analogues. Journal of Medicinal Chemistry, 2008, 51, 2244-2253.	2.9	45
125	Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. European Journal of Endocrinology, 2008, 159, 811-817.	1.9	90
126	[123I]Iodometomidate for Molecular Imaging of Adrenocortical Cytochrome P450 Family 11B Enzymes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2358-2365.	1.8	88

#	Article	IF	Citations
127	Pituitary-Interrenal Interaction in Zebrafish Interrenal Organ Development. Molecular Endocrinology, 2007, 21, 472-485.	3.7	87
128	Impaired Subjective Health Status in 256 Patients with Adrenal Insufficiency on Standard Therapy Based on Cross-Sectional Analysis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3912-3922.	1.8	242
129	Do dehydroepiandrosterone supplements have anti-aging potential?. Nature Reviews Urology, 2007, 4, 302-303.	1.4	0
130	Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. New England Journal of Medicine, 2007, 356, 2372-2380.	13.9	679
131	DHEA: why, when, andÂhow much â€“ DHEA replacement inÂadrenal insufficiency. Annales D'Endocrinologie, 2007, 68, 268-273.	0.6	21
132	Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clinical Endocrinology, 2006, 64, 060222010233001.	1.2	97
133	Intraoperative haemodynamic stability in patients with phaeochromocytoma ? minimally invasive vs conventional open surgery. Clinical Endocrinology, 2006, 65, 352-358.	1.2	28
134	Efficacy of Adjuvant Radiotherapy of the Tumor Bed on Local Recurrence of Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4501-4504.	1.8	224
135	Adrenocortical Carcinoma - Improving Patient Care by Establishing New Structures. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, 45-51.	0.6	76
136	Evidence against a role of human airway trypsin-like protease â€“ the human analogue of the growth-promoting rat adrenal secretory protease â€“ in adrenal tumourigenesis. European Journal of Endocrinology, 2005, 152, 143-153.	1.9	17
137	AKT Is Highly Phosphorylated in Pheochromocytomas But Not in Benign Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4366-4370.	1.8	43
138	Peroxisome Proliferator-Activated Receptor-Î³ Agonists Suppress Adrenocortical Tumor Cell Proliferation and Induce Differentiation. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3886-3896.	1.8	67
139	Congenital Isolated Adrenocorticotropin Deficiency: An Underestimated Cause of Neonatal Death, Explained byTPITGene Mutations. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1323-1331.	1.8	116
140	Management of adrenal insufficiency in different clinical settings. Expert Opinion on Pharmacotherapy, 2005, 6, 2407-2417.	0.9	42
141	Mitotane for adrenocortical carcinoma treatment. Current Opinion in Investigational Drugs, 2005, 6, 386-94.	2.3	90
142	The Adrenal Secretory Serine Protease AsP Is a Short Secretory Isoform of the Transmembrane Airway Trypsin-Like Protease. Endocrinology, 2004, 145, 1898-1905.	1.4	30
143	Management of adrenocortical carcinoma. Clinical Endocrinology, 2004, 60, 273-287.	1.2	185
144	N-Terminal Proopiomelanocortin Acts as a Mitogen in Adrenocortical Tumor Cells and Decreases Adrenal Steroidogenesis. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2171-2179.	1.8	64

#	Article	IF	Citations
145	Clodronate inhibits adrenocortical cell proliferation and P450c21 activity. Journal of Endocrinology, 2002, 174, 509-516.	1.2	11
146	Addisonian crisis in a young man with atypical anorexia nervosa. , 0, .		1